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Introduction
In 2003, WHO launched the ambitious 3 by 5 strategy,1 
which recommends simpliﬁ ed management plans for 
the prescription and surveillance of antiretroviral therapy 
in resource-constrained settings, with the aim of ensuring 
that 3 million people receive treatment by the end of 
2005.2 An interim report in June, 2005, revealed that only 
1 of the 6 million people currently in need of antiretroviral 
treatment were actually receiving them.3,4 Most of these 
patients were living in middle-income countries such as 
Brazil, Thailand, and South Africa. The report concluded 
that the 3 by 5 programme would not reach its goal.
Scarce ﬁ nancial and human resources and inadequate 
health-care infrastructure are major challenges to the 
scaling up of treatment in sub-Saharan Africa. Models of 
care must be adapted to these circumstances, accounting 
for the few trained health personnel, diﬀ erent groups of 
patients compared with high-income countries (increased 
proportions of children and women of child-bearing age 
aﬀ ected), restricted drug availability and procurement, 
inadequate access to monitoring equipment, and few 
extra funds. Data for ongoing experiences and patients’ 
outcomes in diﬀ erent models of care are still scarce and 
could greatly contribute to the improvement and transfer 
of such models. The medical non-governmental 
organisation Médecins Sans Frontières (MSF) currently 
provides highly active antiretroviral therapy (HAART) to 
more than 56 000 patients in 56 projects worldwide and 
actively participates in implementing scaling-up and 
simpliﬁ cation procedures.5,6 
This study aimed to assess the eﬀ ectiveness of the most 
rapidly expanding and largest MSF programme in the 
rural district of Chiradzulu in Malawi by analysis of 
survival indicators, CD4 count evolution, virological 
response, and adherence.
Methods
Setting
Malawi is one of the poorest countries in southern Africa 
with a yearly health-care expenditure of US$11·8 per 
capita. HIV prevalence was estimated at 19·8% in people 
attending antenatal clinics in 2003, and of a population 
of 10·5 million inhabitants, 900 000 were estimated to be 
infected with HIV by 2003.7 HIV/AIDS is the leading 
cause of death in the most productive age group (20–49 years) 
and greatly aﬀ ects life expectancy, which at 38·5 years is 
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Summary 
Background The recording of outcomes from large-scale, simpliﬁ ed HAART (highly active antiretroviral therapy) 
programmes in sub-Saharan Africa is critical. We aimed to assess the eﬀ ectiveness of such a programme held by 
Médecins Sans Frontières (MSF) in the Chiradzulu district, Malawi.
Methods We scaled up and simpliﬁ ed HAART in this programme since August, 2002. We analysed survival indicators, 
CD4 count evolution, virological response, and adherence to treatment. We included adults who all started HAART 
6 months or more before the analysis. HIV-1 RNA plasma viral load and self-reported adherence were assessed on a 
subsample of patients, and antiretroviral resistance mutations were analysed in plasma with viral loads greater than 
1000 copies per mL. Analysis was by intention to treat.
Findings Of the 1308 patients who were eligible, 827 (64%) were female, the median age was 34·9 years (IQR 
29·9–41·0), and 1023 (78%) received d4T/3TC/NVP (stavudine, lamivudine, and nevirapine) as a ﬁ xed-dose 
combination. At baseline, 1266 individuals (97%) were HAART-naive, 357 (27%) were at WHO stage IV, 311 (33%) 
had a body-mass index of less than 18·5 kg/m², and 208 (21%) had a CD4 count lower than 50 cells per μL. At follow-
up (median 8·3 months, IQR 5·5–13·1), 967 (74%) were still on HAART, 243 (19%) had died, 91 (7%) were lost to 
follow-up, and seven (0·5%) discontinued treatment. Low body-mass index, WHO stage IV, male sex, and baseline 
CD4 count lower than 50 cells per μL were independent determinants of death in the ﬁ rst 6 months. At 12 months, 
the probability of individuals still in care was 0·76 (95% CI 0·73–0·78) and the median CD4 gain was 165 (IQR 
67–259) cells per μL. In the cross-sectional survey (n=398), 334 (84%) had a viral load of less than 400 copies per mL. 
Of several indicators measuring adherence, self-reported poor adherence (<80%) in the past 4 days was the best 
predictor of detectable viral load (odds ratio 5·4, 95% CI 1·9–15·6). 
Interpretation These data show that large numbers of people can rapidly beneﬁ t from antiretroviral therapy in rural 
resource-poor settings and strongly supports the implementation of such large-scale simpliﬁ ed programmes in 
Africa.
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one of the lowest in the world.7 Chiradzulu district 
consists of 250 000 inhabitants, most of whom are poor 
self-suﬃ  cient farmers, with two hospitals and ten rural 
health centres. According to HIV prevalence and the 
proportion of patients with advanced disease, about 6000 
people in the district are regarded to be in urgent need of 
HAART.
Study population 
In collaboration with the Malawian Ministry of Health 
and Population, MSF began an HIV programme in 
Chiradzulu in 1997. HAART was begun free of charge in 
2001 at the district hospital. HAART initiation criteria 
were WHO stage IV irrespective of CD4 count, and WHO 
stages I, II, or III with CD4 counts lower than 200 cells 
per μL according to WHO recommendations.2 CD4 
counts were initially measured by manual techniques 
(Dynabead, Dynal Biotech SA, Compiègne, France), and 
later by semi-automated techniques (Cyﬂ ow counter, 
Partec, Münster, Germany) that have been used since 
mid-2003. All laboratory tests took place at the laboratory 
of the district hospital by two technicians. 
Of 2928 HIV-infected patients who were on HAART up 
to April 15, 2004, 1308 adults who started HAART 6 months 
or more before were included in the analysis (ﬁ gure 1). 
Medical background and follow-up information were 
routinely obtained at every consultation on standardised 
forms and entered into FUCHIA monitoring software 
(follow-up and care of HIV infection and AIDS, Epicentre, 
Paris, France).
Treatment
The availability of an easy-to-use ﬁ rst-line regimen has 
been fundamental to the development of a large-scale 
programme with few resources. From October, 2002, 
treatment was based on the ﬁ xed-dose combination of 
stavudine (d4T), lamivudine (3TC), and nevirapine (NVP; 
Triomune, Cipla, Mumbai, India). MSF has been using 
this generic regimen for some time, well before WHO 
prequaliﬁ cation. This regimen was initially validated 
through internal MSF drug qualiﬁ cation procedures based 
on WHO recommendations and was then prequaliﬁ ed by 
WHO.8,9 The regimen is now recommended by WHO and 
shown to have an excellent safety and eﬃ  cacy.2,10 When 
available, two doses of Triomune (d4T 30 mg or 40 mg) 
were used accordingly to patients’ bodyweight to keep d4T-
related toxic eﬀ ects to a minimum. Patients who are 
intolerant to this combination are oﬀ ered other regimens 
based on efavirenz (EFV; Merck Sharp Dohme, Manati, 
Puerto Rico) together with a d4T-3TC combination 
(Ranbaxy, Dewas, India).
From August, 2002, key steps were taken to adapt the 
programme towards scaling up (panel).11 HAART was 
then initiated after decentralisation by the mobile HIV 
team during their bimonthly visits in the health centres 
and the peripheral hospital. Overall, these adaptations 
have allowed the programme to scale up from initially 
few monthly inclusions (mean 16 patients per month 
before August, 2002) to more than 100 patients in May, 
2003 (mean 139 per month in 2003), and to almost 
220 patients per month in 2004. At the time of the study 
Panel: Adaptations of HAART programme towards 
scaling up
● Disbanding of the previously established selection 
committee with immediate referring of the eligible 
patients to a counsellor
● Implementation of group HAART counselling sessions
● Because individual testing was not feasible, no systematic 
baseline CD4 count was done from 2003 and HAART was 
initiated according to clinical criteria only (WHO stage III 
or IV), as recommended by WHO when CD4 testing was 
not available2 
● Yearly CD4 count for all the patients as the only routine 
monitoring blood test undertaken; other tests (cell blood 
count, chemistries) done only at initiation or if needed
● Introduction of a ﬁ xed-dose combination (Triomune), 
which is known to facilitate adherence (one pill twice a 
day) and drug supply
● Running of the HIV clinic in the district hospital 5 days a 
week 
● Decentralisation of HAART consultations through a 
mobile HIV clinic from the district hospital to the ten rural 
health centres and the peripheral hospital since early 2003
● Monthly follow-up visits by a clinician until stabilisation 
on antiretroviral drugs
● Bimonthly visits by dispensing nurses after stabilisation 
on antiretroviral drugs (for symptom questioning, 
antiretroviral prescriptions, and pill counts). A clinician 
was seen if symptoms were reported on questioning
1308 patients who started 
            HAART 6 months or  
            more before included 
            in analysis
967 on HAART for at least
         6 months
557 not selected
243 deaths
   91 lost to follow-up
     7 stopped HAART
410 patients in subsample
   398 patients assessed in
            cross-sectional
            virological and adherence 
            survey
12 refused
Figure 1: Study proﬁ le
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in April, 2004, 2928 patients had begun HAART in the 
programme.
Cross-sectional virological survey
Between Jan 1 and April 15, 2004, a cross-sectional survey 
was undertaken to assess the virological status of patients 
still on treatment. All patients aged 18 years or older, who 
had been receiving HAART for 6 months or more, and 
who presented to the HIV clinic during the study were 
regarded as eligible. With an expected prevalence of 
virological failure of 20%, a precision of 3%, and a type I 
error of 0·05, a sample size of 400 people was targeted. A 
subsample of patients with an even identiﬁ cation number 
from the patients’ register was chosen. Plasma samples 
were obtained after blood sample centrifugation and 
immediately stored at –80ºC. All samples were sent in 
dry ice under strict cold-chain procedures to the Purpan 
Hospital Virology Unit (Toulouse, France), where plasma 
viral loads were measured with the Amplicor HIV-1 
Monitor version 1·5 assay (Roche Diagnostics, Meylan, 
France), which measures non-clade B HIV-1 subtype 
RNA.12 For viral loads greater than 1000 copies per mL, 
HIV-1 reverse transcriptase genotyping and identiﬁ cation 
of HIV subtypes were undertaken at the same time.13,14 
The resistance proﬁ les to antiretroviral molecules were 
deﬁ ned according to National Agency for AIDS Research 
(ANRS) algorithms.15 Ethics approval for the survey was 
obtained from the ethics committee of the Malawi 
Ministry of Health and written consent was obtained 
from all participants.
Cross-sectional self-reported adherence survey
All patients included in the cross-sectional virological 
survey were also interviewed with a simple adherence 
questionnaire, given face-to-face in the local language by 
interviewers not linked to the medical team. The 
questionnaire was adapted from AIDS clinical trial group 
(ACTG) adherence follow-up questionnaires and the 
MASRI questionnaire.16,17 Patients were asked to report 
the daily number of antiretroviral pills they had missed 
during the past 4 days, as well as their perceived 
adherence during the 28 days before the visit, as 
measured by a visual analogue scale. Patients were also 
asked the main reasons for non-adherence. We used 
three indicators to measure adherence with self-reports. 
First, patients were classiﬁ ed as highly adherent if they 
reported to have taken 100% of their prescribed dose 
during the past 4 days, moderately adherent if they have 
taken 80–99%, or non-adherent if they have taken 80% or 
less. A second measure of adherence in the previous 
28 days was simply based on the visual analogue scale to 
classify patients into highly adherent (100%), moderately 
adherent (80–99%), and non-adherent (<80%) groups. 
We obtained a speciﬁ c measure of high adherence with a 
third combined indicator, using an approach already 
adopted in studies with a similar way of questioning but 
based on self-administered questionnaires.18 From the 
classiﬁ cation of adherence in the past 4 days, highly 
adherent patients were reclassiﬁ ed as moderately 
adherent if they reported to have inadequately followed 
the prescribed schedule of their prescriptions, or did not 
report 100% adherence in the previous 28 days on the 
visual analogue scale.
Another estimate of patients’ adherence not based on 
self-report was derived from the examination of patients’ 
pill boxes and the counting of pills actually taken with 
respect to the number of pills prescribed. We referred to 
this measure as the pill count.
Statistical analysis
Product-limit estimates (Kaplan-Meier) were calculated to 
assess the probability of survival and remaining in care at 
12 and 24 months since HAART initiation, with all patients 
analysed by an intention-to-treat basis. Patients alive and 
in care on April 15, 2004, were right-censored on the date 
of their last visit before this date. At ﬁ rst, we calculated the 
probabilities of surviving at 12 and 24 months by just 
using death events. Patients with more than 2 months’ 
delay with respect to the scheduled follow-up visit and 
who could not be traced were regarded as lost to follow-up. 
A second survival analysis to estimate the probability of 
patients remaining in care was done with events counted 
as patients who died or who were lost to follow-up.
We used a Cox model to identify independent predictors 
of deaths occurring in the ﬁ rst 6 months after HAART 
initiation. Factors included in the model were baseline data 
such as age, sex, CD4 cell count or WHO clinical stage if 
CD4 counts were missing, body-mass index, drug regimen 
used, decentralised follow-up, and year of HAART 
initiation. According to the evolution of the treatment 
programme, years 2001 and 2002 were compared with 
2003 (the year when follow-up of patients had been 
simpliﬁ ed). Because some patients started HAART on the 
sole basis of clinical assessment (with no baseline CD4 
count), we used a variable deﬁ ning patients’ clinico-
immunological status based either on baseline CD4 count 
if available or on WHO staging when CD4 cells were not 
counted. For this variable, CD4 counts greater than 50 cells 
per μL were used as the reference category. We used logistic 
regression analysis to identify factors associated with 
virological failure (viral load >1000 copies per mL). 
A logistic regression analysis was done on treatment-
naive patients to identify which indicator among the pill 
counts and the three self-reported adherence measures 
was the best predictor of detectable viral load (>400 copies 
per mL). We used Stata 8.2 software for analysis (Stata 
Corp). 
Role of the funding source
MSF participated in the study design and data collection. 
The Sidaction did not participate in any part of the study 
process. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication. 
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Results
Of the 1308 adults who started HAART 6 months or 
more before and who were included in the analysis 
(ﬁ gure 1), 68 (5%) started HAART in 2001, 300 (23%) in 
2002, and 940 (72%) in 2003. For 501 (47%) of 1076 patients 
for whom the information was available, a decentralised 
follow-up in the health centres was implemented. Table 1 
summarises the baseline characteristics of all the patients 
in our study. 
Figure 1 shows the study proﬁ le, for clinico-
immunological outcomes; median duration of follow-up 
was 8·3 months (IQR 5·5–3·1). Most deaths (187 [77%] of 
243) occurred in the ﬁ rst 6 months after HAART initiation 
(median time to death 2·6 months, IQR 1·0–5·6). Of the 
967 patients still on HAART, 757 (78%) were on d4T/3TC/
NVP, 151 (16%) on AZT (zidovudine)/3TC/NVP, 29 (3%) 
on d4T/3TC/EFZ, 18 (2%) on AZT/3TC/EFZ, nine (1%) 
on an nelﬁ navir-protease-inhibitor-based second-line 
regimen, and three had other prescriptions. 
Overall, 879 (91%) individuals were still on their original 
regimen and 88 (9%) had to change one or two 
antiretroviral drugs (47 for drug intolerance). Of the 
1308 patients in the cohort, 66 (5%) were reported to have 
stopped their treatment because of severe drug intolerance, 
of which 27 stopped AZT (21 for anaemia, one for 
neutropenia, three for other reasons, two for unknown 
reasons), 15 stopped d4T (11 for peripheral neuropathy, 
one for myopathy, three for unknown reasons), 22 stopped 
NVP (13 for skin toxic eﬀ ects, six for hepatotoxic eﬀ ects, 
three for unknown reasons), and two stopped EFV (one 
for skin rash, one for insomnia).
With only death events accounted for, Kaplan-Meier 
probability of survival was 0·81 (95% CI 0·79–0·83) at 
12 months and 0·72 (0·68–0·76) at 24 months. With both 
death and loss to follow-up events accounted for, the 
probability of remaining in care was 0·76 at 12 months 
and 0·66 at 24 months (ﬁ gure 2).
Of patients with available CD4 counts at baseline 
(n=980), median gain of CD4 cells was 139 cells per μL 
(IQR 63–234) at 6 months (n=102) and 165 (67–259) at 
12 months (n=192). At 12 months, only eight (4%) of 
215 patients with a CD4 test available had a CD4 count 
still lower than 50 cells per μL whereas 144 (67%) had CD4 
counts higher than 200 cells per μL. 
After factors associated with early deaths (occurring in 
the ﬁ rst 6 months of HAART initiation) were analysed by 
a multivariate Cox model (n=925), four baseline factors 
could be independently identiﬁ ed: body-mass index of 
less than 18·5 kg/m², male sex, baseline CD4 count lower 
than 50 cells per μL, and WHO stage IV without CD4 test 
at baseline (table 2). Age at initiation, type of antiretroviral 
treatment used, period of initiation, and care from health 
centres (rather than care from hospitals) were not 
associated with early death in this analysis.
Of the 967 patients still on treatment after 6 months, a 
subsample of 410 patients was chosen for virological 
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Figure 2: Kaplan-Meier curve of patients who started HAART 6 months or 
more before and remaining in care in the Chiradzulu programme, Malawi 
(n=1298) 
Whole cohort (n=1308) Survey group (n=398)
Demography
Female 827 (64%) 275 (69%)
Median age (years [IQR]) 34·9 (29·9–41·0) 34·0 (28·9–40·3)
HAART-naive 1266 (97%) 384 (96%)
Clinico-immunology
WHO stage at HAART initiation
Stage I/II 232 (18%) 72 (18%)
Stage III 718 (55%) 230 (58%)
Stage IV 357 (27%) 96 (24%)
Body-mass index (n) 943 303
Median (kg/m2 [IQR]) 19·8 (17·9–22·1) 20·0 (18·3–22·2)
<18·5 kg/m2 311 (33%) 84 (28%)
CD4 T-cell counts at initiation (n) 980 327
Median number of cells per µL (IQR) 112 (59–176) 114 (66–177)
Count <50 cells per µL 208 (21%) 56 (17%)
Treatment
Initial antiretroviral treatment
d4T/3TC/NVP 1023 (78%) 299 (75%)
AZT/3TC/NVP 256 (20%) 90 (23)
AZT/3TC/EFZ 12 (1%) 5 (1%)
d4T/3TC/EFZ 14 (1%) 2 (0·5%)
AZT/3TC/IND 2 2 (0·5%)
d4T/3TC/RIT 1 ..
Follow-up time on HAART 
Median for all patients (months [IQR]) 8·3 (5·5–13·1) 9·5 (7·4–15·2)
Outcomes
Deaths 243 (19%) ..
Loss to follow-up 91 (7%) ..
Stopped treatment 7 (0·5%) ..
Still on HAART 967 (74%) ..
Data are number of patients (%) unless stated otherwise.
Table 1: Baseline characteristics of patients
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assessment. Of these individuals, 12 refused to participate 
(ﬁ gure 1). Baseline characteristics for the 398 people in 
the cross-sectional virological survey did not diﬀ er 
signiﬁ cantly from those in the entire cohort (table 1). No 
women had previously received single-dose NVP to 
prevent mother-to-child transmission. 299 (75%) initiated 
the 3TC/d4T/NVP regimen as a ﬁ xed-dose combination. 
Median follow-up duration was 9·5 months (IQR 
7·4–15·2), with 245 (62%) patients already on HAART 
for 6–12 months, 80 (20%) for 12–18 months, 39 (10%) 
for 18–24 months, and 34 (9%) for more than 24 months. 
Median CD4 gain was 138 cells per μL (IQR 69–219) at 
6 months (n=45) and 176 cells per μL (97–282) at 
12 months (n=79).
Viral loads could be measured for 397 patients; 
334 (84%) had less than 400 copies per mL and 345 (87%) 
had less than 1000 copies per mL. Of the 52 (13%) patients 
with a viral load higher than 1000 copies per mL, only 
19 (5%) had counts of more than 30 000 copies per mL, a 
threshold indicator for major virological failure (table 3). 
In the multivariate logistic regression model, only 
previous exposure to antiretroviral treatment (odds ratio 
5·06, 95% CI 1·34–19·1), when compared with HAART-
naive patients, was associated with virological failure 
(viral load >1000 copies per mL). Other baseline 
characteristics (age, sex, WHO stage, body-mass index, 
CD4 count), period of HAART initiation, time of follow-
up, gain of CD4 count at 6 months, or body-mass index at 
the time of the survey were not statistically associated 
with virological failure in the model.
HIV reverse transcriptase genotyping was done for the 
52 patients who had viral loads higher than 1000 copies 
per mL; two samples were not interpretable because of 
failed PCR ampliﬁ cation. According to reverse 
transcriptase sequences, all viruses were identiﬁ ed as the 
HIV-1C subtype. Three (6%) interpretable sequences did 
not show any mutations, 42 (84%) presented NRTI 
(nucleoside reverse transcriptase inhibitor) mutations, 
and 47 (94%) non-NRTI mutations. The most frequent 
NRTI mutation was the 3TC-induced Met184Val mutation 
(n=38, 76%), whereas the Thr215Tyr/Phe mutation 
induced by d4T was rarely seen (n=6, 12%). The Lys65Arg 
mutation, known to confer resistance to tenofovir, was 
recorded in ﬁ ve (10%) patients taking non-tenofovir-
based regimens. 
Of the non-NRTI mutations, Lys103Asn (n=22, 44%) 
and Tyr181Cys/Ile (n=14, 28%) were more frequently 
identiﬁ ed than Lys101Glu/Gln (n=9, 18%), Gly190Ala/Ser 
(n=9, 18%), or Val106Met/Ala (n=7, 14%). According to 
ANRS algorithms, 42 patients with viral loads greater 
than 1000 copies per mL were resistant to both 3TC and 
NVP/EFV (of which six individuals were also resistant to 
d4T), and ﬁ ve were resistant to NVP/EFV only.15
For adherence analysis with the pill count (n=367), 334 
(91%) patients were classiﬁ ed as highly adherent (235, 
64%) or moderately adherent (99, 27%) and 33 (9%) as 
non-adherent. By use of self-reported adherence in the 
past 4 days (n=398), 383 (96%) patients were regarded as 
highly adherent (375, 94%) or moderately adherent 
(8, 2%), and 15 (4%) as non-adherent. With the combined 
indicator based on self-reports (n=398), 365 (92%) 
patients could be classiﬁ ed as highly adherent (301, 76%) 
or moderately adherent (64, 16%) and 33 (8%) as non-
adherent.
Self-reported adherence in the past 4 days was the best 
predictor of detectable viral load (odds ratio 
5·4, 95% CI 1·9–15·6) whereas the combined indicator 
was only marginally associated with this outcome 
(2·3, 1·0–5·2). However, the pill count (1·7, 0·7–4·1) and 
visual analogue scale (1·9, 0·8–4·5) were not signiﬁ cantly 
associated with detectable viral load; neither variable was 
Number of individuals (%) (n=397) 95% CI Cumulative %
<40 copies per mL 275 (69%) 65–74 69%
40–400 copies per mL 59 (15%) 11–18 84%
400–1000 copies per mL 11 (3%) 1–4 87%
1000–5000 copies per mL 19 (5%) 3–7 92%
5000–30 000 copies per mL 14 (3%) 2–5 95%
≥30 000 copies per mL 19 (5%) 3–7 100%
Table 3: Viral load measures of 397 patients in cross-sectional virological survey
Univariate analysis Multivariate analysis
Age
>35 years 1 ..
≤35 years 1·09 (0·80–1·49) ..
HAART initiation
2003 1 ..
2002 1·35 (0·97–1·88) ..
2001 0·70 (0·28–1·79) ..
Antiretroviral regimen
AZT-based 1 ..
d4T-based 1·03 (0·70–1·52) ..
Follow-up
Centralised process 1 ..
Decentralised process 1·26 (0·91–1·74) ..
Sex
Female 1 ..
Male 1·76 (1·29–2·39) 1·63 (1·15–2·31)
Body-mass index*
≥18·5 kg/m2 1 ..
<18·5 kg/m2 3·56 (2·42–5·26) 2·92 (2·04–4·17)
CD4 at baseline
≥50 cells per µL 1 ..
<50 cells per µL 2·19 (1·51–3·19) 1·64 (1·07–2·53)
No CD4, WHO stage I/II 1·07 (0·42–2·74) 0·72 (0·18–2·94)
No CD4, WHO stage III 1·14 (0·68–1·91) 0·96 (0·55–1·68)
No CD4, WHO stage IV 3·04 (1·95–4·75) 2·47 (1·45–4·20)
Data are hazard ration (95% CI). *At baseline.
Table 2: Cox model analysis of factors associated with early death in the 
Chiradzulu programme, Malawi (n=1308)
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signiﬁ cant after adjustment for possible confounders or 
predictors. By contrast, the strength of the association 
between adherence in the past 4 days and viral load did 
not change even after adjustment for the duration of 
follow-up and other possible cofactors (sex, age, baseline 
body-mass index, and CD4 count). Of potential causes 
for missing pills (n=398), individuals being away from 
home (n=137), forgetting to take drugs (n=119), running 
out of pills (n=36), feeling sick (n=31), or trying to avoid 
side-eﬀ ects (n=17) were the most frequently reported. 
Discussion
Our study of a large-scale simpliﬁ ed HAART programme 
revealed that more than three-quarters of patients 
remained in care at 12 months with a median CD4 gain 
of 165 cells per μL. Low body-mass index, WHO stage IV, 
male sex, and a low baseline CD4 count were associated 
with early mortality. Of assessed patients still on HAART 
for more than 6 months, more than 80% had undetectable 
viral loads (<400 copies per mL). Self-reported adherence 
during the past 4 days was the best predictor of detectable 
viral load. 
The Chiradzulu programme diﬀ ers from most HAART 
programmes described so far in Africa with respect to the 
scaling-up and simpliﬁ cation procedures used and the 
number of patients already on treatment.19–21 Currently, 
very few data from programmes currently involved in 
scaling-up HAART have been reported.21–24 Clinical, 
immunological, and virological treatment outcomes 
obtained in our study are comparable with those described 
in cohorts from developing as well as developed 
countries,21–26 and indicate that despite scarce medical and 
monitoring resources, a large cohort of patients with 
advanced stages of HIV disease could clearly beneﬁ t from 
ﬁ rst-line antiretroviral treatment. 
 Similar to other regions of Malawi, the Chiradzulu 
district health system is chronically short-staﬀ ed and MSF 
has had to employ ﬁ ve clinical oﬃ  cers, three dispensing 
nurses, seven counsellors, a pharmacy technician, and a 
medical doctor to provide outpatient antiretroviral services 
in collaboration with personnel from the Ministry of 
Health (two clinical oﬃ  cers, and nurses from health 
centres). Clinicians mostly focus on patients who are to 
begin or who have just begun antiretroviral treatment. 
Dispensing nurses’ tasks are to detect poorly adherent 
patients and dispense the drugs. They also have the role of 
triage for patients who have already been stabilised on 
antiretroviral drugs. One MSF nurse was also in charge of 
tracing followed up patients. Counsellors deal with 
patients’ education and psychological support. In the 
health centres during bimonthly visits, the MSF mobile 
HIV team was working in collaboration with Ministry of 
Health nurses who were in charge of the patients on all 
the other days.
We believe that free treatment is an important reason for 
assuring retention in antiretroviral treatment and 
sustained long-term immuno-virological response. This 
beneﬁ t is well illustrated by the situation in Brazil, where a 
free national programme has had wide coverage with very 
satisfactory outcomes.27–29 However, the scaling-up process 
has not been without major challenges, and several 
institutional and individual beliefs and attitudes about 
provision of HIV care have had to be overcome. Doctors 
were initially uncomfortable in shifting responsibility 
towards nurses, although acceptance came quickly with 
the beneﬁ ts of the treatment of such a large number of 
patients. Such a shift was necessary because of the chronic 
shortage of medical staﬀ  in the district and despite the 
input of substantial human resources by MSF. Similarly, 
the scarcity of trained laboratory staﬀ  is one of the factors 
preventing individual immunological and virological 
monitoring in this and other settings. 
The high initial death rate recorded in our programme 
was similar to that seen in other African cohorts and in 
developed countries during the early HAART era for 
severely immunocompromised patients.20,21,23,30 Death and 
loss to follow-up events mostly occur in the ﬁ rst 6 months 
after HAART initiation. Indeed, most patients die at 
home and the ultimate causes of death remain often 
unspeciﬁ ed. As expected, factors associated with early 
mortality are those indicating an advanced stage of the 
disease at HAART initiation. Other factors inherent to 
the programme itself, such as the period of inclusion and 
follow-up in the health centres (decentralisation), did not 
aﬀ ect survival. Thus, this early death rate might show the 
late presentation of the patients to the clinic with 
overwhelming opportunistic infection or early immune 
reconstitution syndrome induction.31 Serial changes in 
body-mass index are important prognostic indicators of 
survival in resource-rich settings.32,33 In sub-Saharan 
Africa, the burden of intercurrent infections diﬀ ers 
substantially, and whether body-mass index is a useful 
simple clinical marker of survival is debatable. Our data 
and recent studies suggest that body-mass index at the 
time of HIV diagnosis or at HAART initiation remains 
an important survival predictor in resource-poor 
settings.33,34 Unexpectedly, male sex was also independently 
associated with early death. Since such an eﬀ ect has not 
been reported previously in other African cohort 
studies,19–21 unidentiﬁ ed confounding factors could also 
contribute to early death. 
Such early mortality rates represent important 
challenges faced by the HIV programmes in sub-Saharan 
Africa to rapidly and eﬃ  ciently treat large numbers of 
patients. Strategies are needed to help earlier access to 
HAART, to improve the diagnosis of opportunistic 
infections, and to better identify and manage immune 
reconstitution syndromes. Further studies are also 
needed to investigate nutrition strategies to reduce early 
mortality for patients with very low body-mass index. 
We were concerned that changes in contact time 
between patients and clinicians due to the increasing 
number of patients rapidly enrolled in the scaled-up 
programme could aﬀ ect adherence. Our ﬁ nding that 
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most (84%) patients who survived the ﬁ rst 6 months had 
viral loads lower than 400 copies per mL, was similar to 
that obtained in better-resourced settings and in other 
reported African settings for treatment-naive 
patients.19,20,26,35,36 We recorded that self-reported adherence 
in the past 4 days with a cutoﬀ  of 80% best predicted 
detectable viral loads (>400 copies per mL) in treatment-
naive patients. Our results conﬁ rm that even for the 
ﬁ xed-dose combination regimen, adherence of less than 
80% is detrimental for long-term virological response in 
the maintenance phase of treatment.37 Additionally, our 
results underline that the most appropriate questions for 
adherence measurement could depend on how patients 
are questioned (face-to-face or self-administered) and in 
the sociocultural context, since social desirability or recall 
bias could modulate the answer to some questions. These 
results also show that, in simpliﬁ ed programmes, self-
reported adherence combined with other indicators can 
be regarded as an important proxy of treatment outcome. 
Our result will help deﬁ ne a simple questionnaire to 
detect poorly adherent patients in such settings. 
The high adherence to HAART treatment recorded in 
survivors from our cohort indicate early success of the 
scaling-up approach, and further conﬁ rm the eﬀ ectiveness 
of generic ﬁ xed-dose combinations. Studies in resource-
rich settings show that poor adherence in the maintenance 
phase is crucial for long-term immunovirological success. 
However, the median follow-up time of our patients 
studied is still short (9·5 months, table 1) and because 
adherence to HAART is a dynamic process,18,37 further 
investigation is clearly needed to assess such adherence 
in the medium-term and long-term in this setting.
HIV genotyping of viral loads higher than 1000 copies 
per mL (13%) revealed the presence of mutations expected 
for HIV-1B subtype with respect to the antiretroviral drugs 
prescribed, whereas all viruses analysed were of the 
HIV-1C subtype, for which little is known, since most of 
the current knowledge relates to HIV-1B.38,39 Viral resistance 
is an inevitable consequence of HAART, even in resource-
rich settings with very high adherence, and should not be 
regarded as a barrier to scaling up but as another challenge 
to be faced.40,41 Although legitimate concern exists about 
the spread of viral resistance during scaling up, the 
potential for chaotic drug supply and subsequent resistance 
in the absence of formal programmes is the probable 
alternative. In countries where few patients are exposed to 
suboptimum treatment and a public-health approach is 
taken to HIV management, the potential for widespread 
viral resistance could be less likely than that in resource-
rich settings.42–44 Sentinel monitoring approaches to follow 
HIV resistance emergence in HAART programmes 
should be implemented where possible.45
Our study presents several limitations mainly because it 
analyses the outcomes of an observational cohort with 
routine data monitoring. Indeed, the nature of opportunistic 
infections and comorbidities were incompletely recorded 
and could not be appropriately analysed. Standardisation 
and particular focus on these data in MSF programmes 
should allow more accurate analysis in the near future. 
Causes of death were incompletely recorded mainly 
because patients either died at home or could not be 
diagnosed (because of a lack of appropriate diagnostic 
procedures). Since tracing is not easy, and access to the 
clinic might be diﬃ  cult for many patients, loss to follow-
up was most likely in patients with negative outcomes. To 
consider this problem, we used analyses with a combined 
endpoint of death or loss to follow-up. Finally, with a 
median at 9·5 months, the follow-up on HAART of the 
patients studied was still restricted and long-term analyses 
are clearly needed to fully assess the eﬀ ect of scaling-up 
procedures on global outcomes of the programme and to 
allow some generalisability of the results. 
In conclusion, our study indicates that key steps for 
simpliﬁ cation and scaling up can be safely implemented 
to rapidly and eﬃ  ciently treat large numbers of patients 
even if trained personnel availability will still remain to be 
an important limiting factor.46 
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